
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Oncol. , 13 January 2023
Sec. Genitourinary Oncology
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1125641
This article is a correction to:
MRI radiomics predicts progression-free survival in prostate cancer
A corrigendum on
MRI radiomics predicts progression-free survival in prostate cancer.
by Jia Y, Quan S, Ren J, Wu H, Liu A, Gao Y, Hao F, Yang Z, Zhang T and Hu H (2023) Front. Oncol. 12:974257. doi: 10.3389/fonc.2022.974257
In the published article, there was an error in affiliation 3. Instead of “Department of Radiology, Inner Mongolia International Hospital, Hohhot, China”, it should be “Department of Radiology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: prostate cancer, radiomics, progression-free survival, magnetic resonance imaging, predictions
Citation: Jia Y, Quan S, Ren J, Wu H, Liu A, Gao Y, Hao F, Yang Z, Zhang T and Hu H (2023) Corrigendum: MRI radiomics predicts progression-free survival in prostate cancer. Front. Oncol. 12:1125641. doi: 10.3389/fonc.2022.1125641
Received: 16 December 2022; Accepted: 30 December 2022;
Published: 13 January 2023.
Edited and Reviewed by:
Matteo Ferro, European Institute of Oncology (IEO), ItalyCopyright © 2023 Jia, Quan, Ren, Wu, Liu, Gao, Hao, Yang, Zhang and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hui Wu, dGVycnl3dWh1aUBzaW5hLmNvbQ==; Aishi Liu, bGl1YWlzaGlAc2luYS5jb20=
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.